Previous close | 1.5000 |
Open | 1.4700 |
Bid | 1.4300 x 0 |
Ask | 1.4400 x 0 |
Day's range | 1.4100 - 1.5200 |
52-week range | 1.1100 - 6.2200 |
Volume | |
Avg. volume | 2,164,229 |
Market cap | 465.418M |
Beta (5Y monthly) | 3.02 |
PE ratio (TTM) | N/A |
EPS (TTM) | -6.1050 |
Earnings date | 09 Feb 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 1.92 |
There's more evidence now favoring medical marijuana legalization. But medical marijuana is already legal in most states.
Here is how Aurora Cannabis Inc. (ACB) and Cabaletta Bio, Inc. (CABA) have performed compared to their sector so far this year.
First off, a massive valuation gap must exist between a company's current share price and its fair value estimate. Under normal circumstances, the market is fairly efficient at pricing equities, but sizable valuation gaps can form when Wall Street has serious doubts about a company's business model. Second, and perhaps most importantly, the company must be able to build a solid competitive moat to protect profits over the long-term.